On this page
Anophthalmia/microphthalmia (SOX2)
This condition affects eye development before birth, resulting in eyes that are either completely absent (anophthalmia) or significantly smaller than normal (microphthalmia). The severity varies considerably between affected individuals, and some people may experience involvement of other body systems beyond the eyes.
Overview
Anophthalmia/microphthalmia (SOX2) represents a spectrum of developmental eye disorders arising from disrupted eye formation during early embryonic growth [PMID:16518403]. In anophthalmia, one or both eyes fail to develop entirely, whilst microphthalmia describes eyes that form but remain substantially smaller than typical size. Both manifestations can occur within the same family, reflecting the variable expression of SOX2 pathogenic variants. Prevalence estimates for anophthalmia and microphthalmia as a group suggest these conditions affect approximately 1 in 10,000 individuals, though the proportion attributable specifically to SOX2 variants represents a subset of this figure.
Pathogenic changes in SOX2 represent one recognised genetic cause of this developmental eye disorder, though other genes and non-genetic factors can produce similar features. Beyond ocular involvement, some affected individuals may experience additional developmental differences affecting other organ systems, reflecting the broad role SOX2 plays in early human development [PMID:18025358]. The clinical presentation varies substantially, even amongst family members carrying the same genetic variant, and individualised assessment is recommended.
Early recognition and management through specialist ophthalmology and clinical genetics services form important components of care for affected individuals and their families. Whilst visual outcomes depend on the degree of eye underdevelopment, supportive interventions can address functional and cosmetic aspects, and genetic counselling helps families understand inheritance patterns and reproductive options.
Symptoms & clinical features
The hallmark feature of this condition is the structural underdevelopment of one or both eyes, which becomes apparent at birth or during routine antenatal scanning. In complete anophthalmia, the eye globe is entirely absent, whilst microphthalmia presents with a small eye that may have a range of additional structural differences including coloboma (gaps in eye structures), cataract, or retinal abnormalities. Vision is typically severely reduced or absent in affected eyes, though the degree of visual impairment correlates with the extent of structural underdevelopment.
Beyond the eyes, some individuals with SOX2-related anophthalmia/microphthalmia may exhibit additional features reflecting the gene's role in multiple developmental processes [PMID:12660784]. These can include learning difficulties of variable severity, delays in reaching developmental milestones, growth differences, or genital abnormalities in males. Pituitary hormone deficiencies have been reported in some affected individuals, potentially affecting growth, puberty, or metabolic function. Oesophageal atresia (incomplete formation of the food pipe) represents a less common but recognised associated feature. The presence and severity of non-ocular features varies considerably, with some individuals experiencing isolated eye involvement whilst others have multi-system differences.
Video: Genetics 101
Affected organs
The eyes represent the primary and most consistently affected organs in SOX2-related anophthalmia/microphthalmia. The degree of underdevelopment ranges from subtle microphthalmos with relatively preserved internal eye structures to complete bilateral anophthalmia. Associated eye abnormalities may include structural gaps in the iris, lens, or retina, optic nerve hypoplasia, or anterior segment dysgenesis affecting the front portion of the eye.
The central nervous system may show involvement in some affected individuals, with brain imaging occasionally revealing structural differences including pituitary abnormalities or corpus callosum hypoplasia. The endocrine system can be affected when pituitary development is disrupted, potentially resulting in growth hormone deficiency, hypothyroidism, or other hormonal insufficiencies. The gastrointestinal tract, reproductive system, and skeletal system have been reported to show abnormalities in a subset of cases, though ocular features remain the most consistent clinical finding across affected individuals.
Risks & severity
The severity spectrum of SOX2-related anophthalmia/microphthalmia is broad, ranging from isolated mild microphthalmia with some functional vision to bilateral anophthalmia with complete absence of both eyes and additional systemic involvement. Visual outcomes depend primarily on the degree of structural eye development, with individuals having mild microphthalmia potentially retaining useful vision whilst those with severe microphthalmia or anophthalmia typically have profound visual impairment from birth.
The presence of additional non-ocular features influences overall health outcomes and support needs. Individuals with isolated eye involvement generally have normal life expectancy and cognitive development, whilst those with learning difficulties, endocrine abnormalities, or structural brain differences may require multidisciplinary medical and educational support. Pituitary hormone deficiencies, when present, necessitate ongoing endocrinology input and hormone replacement therapy. The variable expression of SOX2 variants means that clinical severity cannot always be predicted from family history alone, as the same genetic variant can produce different phenotypes in different family members.
Genetic causes
Pathogenic variants in SOX2 cause this form of anophthalmia/microphthalmia by disrupting the normal function of the SOX2 protein during embryonic development. SOX2 belongs to a family of transcription factors, meaning the encoded protein controls whether particular genes become active at specific developmental stages and in defined tissue types. Eye formation depends heavily on SOX2 guiding the activation of numerous downstream genes responsible for building the lens, retina, and optic nerve structures.
This protein also participates in developmental processes outside the visual system, accounting for why some affected individuals show features beyond eye involvement. SOX2 contributes to patterning events in the developing brain, helps orchestrate pituitary gland assembly, and supports tissue formation in additional organs. When pathogenic changes compromise how much working SOX2 protein cells can generate, or damage the protein's capacity to execute its control functions, these developmental programmes become disrupted. Eye construction goes awry, and SOX2-dependent processes in other body regions may likewise be affected.
The majority of disease-causing alterations in SOX2 function as loss-of-function variants, reducing the quantity of functional protein available when cells need it most during critical developmental periods. Examples include nonsense variants that introduce premature termination signals, frameshift changes that corrupt the protein blueprint, and larger deletions eliminating the gene itself or its regulatory sequences. The precise timing and tissue distribution of SOX2 activity across embryonic life determines which organs ultimately manifest structural differences in affected individuals.
- SOX2 SRY-box transcription factor 2
Inheritance pattern
Anophthalmia/microphthalmia (SOX2) follows an autosomal dominant inheritance pattern, meaning a pathogenic variant in just one copy of SOX2 is sufficient to cause the condition. Each child of an affected individual has a 50 per cent chance of inheriting the familial variant and potentially developing features of the condition. However, many cases arise from de novo variants, which are new genetic changes occurring for the first time in the affected individual rather than being inherited from a parent.
When a SOX2 variant occurs de novo, the parents' risk of having another affected child is generally low, though slightly elevated above the general population risk due to the theoretical possibility of germline mosaicism (where some of a parent's egg or sperm cells carry the variant whilst their body cells do not). Affected individuals can pass the variant to their children, though reproductive capacity may be reduced in those with associated genital or endocrine abnormalities. The variable expression characteristic of SOX2 variants means that inheriting the familial genetic change does not guarantee identical clinical features to the affected parent, as severity can differ substantially between generations.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of SOX2-related anophthalmia/microphthalmia typically begins with clinical recognition of the characteristic eye features, either during antenatal ultrasound scanning or at postnatal examination. Detailed ophthalmological assessment establishes the degree of eye underdevelopment and identifies associated structural abnormalities. Brain imaging may be recommended to evaluate for central nervous system involvement, and endocrine assessment helps identify any pituitary hormone deficiencies requiring treatment.
Genetic confirmation is achieved through DNA sequencing of SOX2, which can identify pathogenic variants in a proportion of individuals with bilateral anophthalmia or severe microphthalmia. Detection rates are influenced by the severity and laterality of the eye findings, with more severe bilateral cases yielding higher diagnostic rates. SOX2 appears on the NHS Genomic Medicine Service PanelApp under ophthalmology gene panels for anophthalmia/microphthalmia. Referral to clinical genetics services enables comprehensive genetic testing, interpretation of identified variants, and family counselling. Cascade testing for at-risk relatives may be offered when a pathogenic variant is confirmed, allowing predictive testing or prenatal diagnosis for those who wish to explore these options.
Management & lifestyle
Management of SOX2-related anophthalmia/microphthalmia requires coordinated input from multiple specialties tailored to each individual's specific needs. Ophthalmology assessment establishes baseline visual function and monitors for treatable complications such as glaucoma in microphthalmic eyes. For cosmetic and orbital development purposes, conformers or prosthetic eyes may be fitted, with paediatric specialists experienced in managing anophthalmic sockets guiding this process. Early vision support services, including specialist education input, help maximise functional outcomes and developmental progress.
Endocrinology review is recommended to screen for pituitary hormone deficiencies, with ongoing monitoring and hormone replacement therapy instituted as required. Growth, thyroid function, and pubertal development should be assessed at appropriate ages. Individuals with learning difficulties benefit from neurodevelopmental assessment and educational support planning. Any additional medical issues, such as oesophageal or cardiac abnormalities when present, require appropriate specialist input.
Genetic counselling forms an important component of holistic care, helping families understand the inheritance pattern, recurrence risks, and reproductive options including prenatal diagnosis or preimplantation genetic testing for those planning future pregnancies. Psychological support and connection with patient organisations can provide valuable peer support and practical resources for families adapting to visual impairment and associated features.
UK care pathway
Within the NHS Genomic Medicine Service, individuals with anophthalmia or microphthalmia typically access genetic testing through ophthalmology or clinical genetics referral pathways. The condition appears on relevant ophthalmology gene panels in PanelApp, facilitating access to comprehensive genetic testing when clinical criteria are met. Referral to a clinical genetics service enables detailed family history assessment, genetic testing coordination, and interpretation of results within the family context.
Genetic counsellors provide essential support in helping families understand test results, inheritance patterns, and implications for relatives. They can discuss reproductive options and coordinate predictive testing for at-risk family members when appropriate. Multidisciplinary care involving ophthalmology, clinical genetics, endocrinology, and developmental paediatrics ensures comprehensive assessment and management aligned with individual needs and national best practice frameworks.
Frequently asked questions
Will my child's vision improve as they grow?
Vision outcomes depend on the degree of structural eye development present at birth. The underlying eye structure does not improve with age, so visual potential remains determined by the initial developmental abnormality. Maximising functional vision through early intervention, appropriate visual aids, and developmental support can help children achieve their full potential.
Can anophthalmia or microphthalmia be detected during pregnancy?
Detailed antenatal ultrasound scanning can sometimes identify absent or very small eyes during the second or third trimester. Milder degrees of microphthalmia may not be apparent on routine scans. If anophthalmia/microphthalmia is suspected antenatally and there is a known familial SOX2 variant, prenatal genetic testing can be discussed with clinical genetics services.
Should other family members be tested if my child has a SOX2 variant?
If your child's SOX2 variant arose de novo (new in them), other family members typically do not require testing unless they have relevant clinical features. If the variant was inherited from a parent, cascade testing may be offered to other at-risk relatives who wish to know their genetic status, particularly those planning pregnancies. A genetic counsellor can discuss testing options appropriate to your family situation.
What support is available for children with visual impairment from this condition?
Children with significant visual impairment access support through specialist education services for vision impairment, which can begin from early infancy. Habilitation specialists, specialist teachers, and mobility training help children develop skills for daily living. Voluntary organisations focused on visual impairment provide family support, practical resources, and connections with other families experiencing similar situations.
Are there any treatments that can restore eye development?
Current medical treatments cannot restore eye structures that did not form during embryonic development. Management focuses on maximising any residual vision, addressing cosmetic concerns through prosthetic fitting, and supporting overall development. Research into developmental biology continues, but structural eye formation cannot currently be reversed after birth.